Advertisement

Hepatocellular metastasis recurrence in liver transplant after treatment with direct antiviral agents

  • Silvia Maier
  • Debora Donnini
  • Laura De Luca
  • Claudio Avellini
  • Leonardo Alberto Sechi
  • Giorgio SoardoEmail author
Case Report

Abstract

Chronic HCV liver infection is considered one of the main causes of liver cirrhosis and hepatocellular carcinoma (HCC). For a selected group of patients, orthotopic liver transplantation (OLTx) is the most effective option to cure both liver diseases. After liver transplantation, patients may be at risk of viral infection reactivation and HCC recurrence. HCV recurrence on the transplanted organ can lead to graft cirrhosis and therefore the clearance of virus with antiviral therapies has a pivotal role on the prevention of graft damage. Nowadays, direct antiviral agents (DAAs) represent the choice treatment for HCV recurrence in liver transplanted patients, ensuring high eradication rates. We present the case of a liver transplant recipient who developed, 7 years after OLTx and immediately after a DAAs treatment, a subcutaneous abdominal mass with histological characteristics of HCC.

Keywords

Hepatocellular carcinoma metastasis Orthotopic liver transplantation Hepatitis C infection Direct antiviral agents 

Notes

Compliance with ethical standards

Conflict of interest

All the authors declare they have no conflict of interest.

Human rights

All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

Informed consent was obtained from all patients for being included in the study.

References

  1. 1.
    European Association For The Study Of The Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.CrossRefGoogle Scholar
  2. 2.
    Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2017;67:358–80.CrossRefGoogle Scholar
  3. 3.
    Zamor PJ, deLemos AS, Russo MW. Viral hepatitis and hepatocellular carcinoma: etiology and management. J Gastrointest Oncol. 2017;8:229–42.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.CrossRefGoogle Scholar
  5. 5.
    Roayaie S, Blume IN, Thung SN, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology. 2009;137:850–5.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Kneuertz PJ, Cosgrove DP, Cameron AM, et al. Multidisciplinary management of recurrent hepatocellular carcinoma following liver transplantation. J Gastrointest Surg. 2012;16:874–81.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–38.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    D’Amico F, Schwartz M, Vitale A, et al. Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl. 2009;15:1278–87.CrossRefPubMedGoogle Scholar
  9. 9.
    Duseja A. Staging of hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4(Suppl 3):74–9.CrossRefGoogle Scholar
  10. 10.
    Onen A, Sanli A, Karacam V, et al. Chest-wall metastasis in a patient who underwent liver transplantation due to hepatocellular carcinoma. Heart Lung Circ. 2008;17:156–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Katyal S, Oliver JH, Peterson MS, et al. Extrahepatic metastases of hepatocellular carcinoma. Radiology. 2000;216:698–703.CrossRefGoogle Scholar
  12. 12.
    Strazzulla A, Iemolo RMR, Carbone E, et al. The risk of hepatocellular carcinoma after directly acting antivirals for hepatitis C virus treatment in liver transplanted patients: Is it real? Hepat Mon. 2016;16:e41933.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Reig M, Marino M, Perello C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719–26.CrossRefGoogle Scholar
  14. 14.
    Reig M, Boix L, Bruix J. The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma. Liver Int. 2017;37(Suppl 1):136–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Grandhe S, Frenette CT. Occurrence and recurrence of hepatocellular carcinoma after successful direct-acting antiviral therapy for patients with chronic hepatitis C virus infection. Gastroenterol Hepatol (N Y). 2017;13:421–5.Google Scholar
  16. 16.
    Cucchetti A, D’Amico G, Trevisani F, et al. Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients. Dig Liver Dis. 2018;50:156–62.CrossRefPubMedGoogle Scholar
  17. 17.
    Nagaoki Y, Aikata H, Nakano N, et al. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: a large-scale, long-term cohort study. J Gastroenterol Hepatol. 2016;31:1009–15.CrossRefPubMedGoogle Scholar
  18. 18.
    The ANRS. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol. 2016;65:734–40.CrossRefGoogle Scholar
  19. 19.
    Yang JD, Leise MD. Damned if you do, damned if you don’t: the evolving story of de novo and recurrent hepatocellular carcinoma amongst those treated with direct-acting antivirals for hepatitis C virus. Liver Int. 2017;37:809–11.CrossRefPubMedGoogle Scholar
  20. 20.
    Yang JD, Aqel BA, Pungpapong S, et al. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J Hepatol. 2016;65:859–60.CrossRefPubMedGoogle Scholar
  21. 21.
    Reig M, Boix L, Marino Z, et al. Liver cancer emergence associated with antiviral treatment: an immune surveillance failure? Semin Liver Dis. 2017;37:109–18.CrossRefPubMedGoogle Scholar
  22. 22.
    Muller L, Aigner P, Stoiber D. Type I interferons and natural killer cell regulation in cancer. Front Immunol. 2017;8:304.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Hengst J, Strunz B, Deterding K, et al. Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy. Eur J Immunol. 2016;46:2204–10.CrossRefPubMedGoogle Scholar
  24. 24.
    Walker NF, Scriven J, Meintjes G, et al. Immune reconstitution inflammatory syndrome in HIV-infected patients. HIV AIDS (Auckl). 2015;7:49–64.Google Scholar
  25. 25.
    de’Angelis N, Landi F, Carra MC, et al. Managements of recurrent hepatocellular carcinoma after liver transplantation: a systematic review. World J Gastroenterol. 2015;21:11185–98.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Clavien PA, Lesurtel M, Bossuyt PM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11–22.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Gastroenterology 2019

Authors and Affiliations

  1. 1.Liver Unit, Internal Medicine, Department of Medicine (DAME)University School of Medicine of UdineUdineItaly
  2. 2.Department of Laboratory Medicine, Institute of Pathological AnatomyUniversity School of Medicine of UdineUdineItaly

Personalised recommendations